Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea
Article first published online: 8 DEC 2011
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 73, Issue 1, pages 140–143, January 2012
How to Cite
Kim, S. Y., Jung, S. W., Kim, J. H., Koo, J. S., Yim, H. J., Park, J. J., Chun, H. J., Lee, S. W. and Choi, J. H. (2012), Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. British Journal of Clinical Pharmacology, 73: 140–143. doi: 10.1111/j.1365-2125.2011.04048.x
- Issue published online: 8 DEC 2011
- Article first published online: 8 DEC 2011
- Accepted manuscript online: 20 JUN 2011 11:03PM EST
- Received; 21 January 2011; Accepted; 12 June 2011; Accepted Article; 20 June 2011
- amoxicillin/administration and dosage;
- drug therapy;
- Helicobacter pylori/drug therapy;
- proton pump inhibitors/administration and dosage
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Triple therapy using a proton pump inhibitor with two antibiotics is the standard treatment for H. pylori infection. However, the increasing prevalence of antibiotic resistance has eroded the high success rates initially reported for the standard triple therapy.
WHAT THIS STUDY ADDS
• Compared with standard triple therapy, amoxicillin/lansoprazole dual therapy, given three times daily for H. pylori had a similar eradication rate with fewer side effects.
We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection.
Two hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment.
The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002).
Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea.